MobiHealth News July 31, 2020
Delays in Dexcom G7 trials and manufacturing have pushed the potential launch date beyond 2020.
Dexcom President and CEO Kevin Sayer is “incredibly proud” of what the company is calling “resilient growth” in the second quarter of 2020, according to an earnings call on Tuesday.
Despite having some uncertainty in the impacts of the COVID-19 pandemic, Dexcom was able to produce significant year-over-year growth in Q2 2020.
Sayer attributes much of the growth to a steady increase in knowledge of the company’s continuous glucose monitor (CGM), the Dexcom G6, among patients.
“Even with rising CGM awareness, there remain many people who continue to rely on fingersticks to manage diabetes, and we believe that there remains a significant opportunity for growth...
Today's Sponsors
Today's Sponsor